2-(((1,3-二氧异吲哚-2-基)甲基)吗啉-4-羧酸叔丁酯 | 876147-52-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异吲哚及其衍生物
• 中文名称: 2-(((1,3-二氧异吲哚-2-基)甲基)吗啉-4-羧酸叔丁酯
• 英文名称: N-{4-(tert-butoxycarbonyl)morpholine-2-yl}methylphthalimide
• 英文别名: N-[[4-(tert-butoxycarbonyl)morpholin-2-yl]methyl]phthalimide；N-[{4-(tert-butoxycarbonyl)-2-morpholinyl}methyl]phthalimide；tert-Butyl 2-((1,3-dioxoisoindolin-2-yl)methyl)morpholine-4-carboxylate；tert-butyl 2-[(1,3-dioxoisoindol-2-yl)methyl]morpholine-4-carboxylate
• CAS: 876147-52-3
• 化学式: C₁₈H₂₂N₂O₅
• 分子量: 346.383
• InChiKey: YGEBKFZXBQXUAK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  25
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  76.2
• 氢给体数：
  0
• 氢受体数：
  5

安全信息

• 海关编码：
  2934999090

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: (N-BOC-Morpholin-2-yl)methyl phthalimide
Synonyms: t-Butyl 2-[(1,3-dioxoisoindol-2-yl)methyl]morpholine-4-carboxylate

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: (N-BOC-Morpholin-2-yl)methyl phthalimide
CAS number: 876147-52-3

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C18H22N2O5
Molecular weight: 346.4

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-(((1,3-二氧异吲哚-2-基)甲基)吗啉-4-羧酸叔丁酯 在 一水合肼 、 柠檬酸 、 sodium hydroxide 作用下， 以 乙醇 、 水 、 氯仿 为溶剂， 反应 1.5h， 生成 4-Boc-2-(氨甲基)吗啉
  参考文献：
  名称：

  AMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME

  摘要：

  揭示了一种具有强烈亲和力的化合物，对5-羟色胺-4受体具有亲和力，可用作促进肠动力或改善消化道功能的药剂。具体地，揭示了一种由化学式（1）表示的化合物或其药学上可接受的盐。还具体揭示了一种含有由化学式（1）表示的化合物或其药学上可接受的盐的药物组合物。【在化学式（1）中，Ar代表由化学式（Ar-1）或化学式（Ar-2）表示的基团。】

  公开号：

  US20100249399A1
• 作为产物：
  描述：

  碳酸二叔丁酯 、 2-(1,4-嗪-2-基甲基)-1H-异吲哚-1,3(2H)二酮 在 三乙胺 作用下， 以 氯仿 为溶剂， 反应 4.0h， 生成 2-(((1,3-二氧异吲哚-2-基)甲基)吗啉-4-羧酸叔丁酯
  参考文献：
  名称：

  WO2007/37518

  摘要：

  公开号：

文献信息

• [EN] BENZOIMIDAZOLE COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS DE BENZOIMIDAZOLE ET UTILISATIONS DE CEUX-CI
  申请人：ASTRAZENECA AB

  公开号：WO2011062550A1

  公开（公告）日：2011-05-26

  This invention generally relates to substituted benzoimidazole compounds, particularly methyl 2-((2-(2,6-difluoro-4-(methylcarbamoyl)phenyl)-5-methyl-1H- benzo[d]imidazol-1-yl)methyl)morpholine-4-carboxylate and salts thereof. This invention also relates to pharmaceutical compositions and kits comprising such a compound, uses of such a compound (including, for example, treatment methods and medicament preparations), processes for making such a compound, and intermediates used in such processes.

  这项发明通常涉及取代苯并咪唑化合物，特别是甲基2-((2-(2,6-二氟-4-(甲基氨基甲酰)苯基)-5-甲基-1H-苯并[d]咪唑-1-基)甲基)吗啡啶-4-羧酸酯及其盐。这项发明还涉及包含这种化合物的药物组合物和试剂盒，以及这种化合物的用途（包括治疗方法和药物制剂等），制备这种化合物的方法，以及在这些过程中使用的中间体。
• [EN] COMBINATION THERAPIES FOR TREATING PAIN<br/>[FR] TRAITEMENTS COMBINÉS POUR LE TRAITEMENT DE LA DOULEUR
  申请人：ASTRAZENECA AB

  公开号：WO2012158117A1

  公开（公告）日：2012-11-22

  This invention generally relates to a combination therapy comprising the use of a substituted benzoimidazole compound and a nonsteroidal anti-inflammatory drug (NSAID) or acetaminophen, and, in particular, to the use of methyl 2-((2-(2,6-difluoro-4- (methylcarbamoyl)phenyl)-5-methyl-1H-benzo[d]imidazol-1-yl)methyl)morpholine-4- carboxylate or a salt thereof and an NSAID or acetaminophen to treat pain. This invention also relates to the combinations themselves, uses of such a combination, and pharmaceutical compositions and kits comprising such a combination.

  这项发明通常涉及一种联合疗法，包括使用一种取代苯并咪唑化合物和一种非甾体抗炎药（NSAID）或对乙酰氨基酚，并且特别涉及使用甲基2-((2-(2,6-二氟-4-(甲基氨基)苯基)-5-甲基-1H-苯并[d]咪唑-1-基)甲基)吗啡啶-4-羧酸酯或其盐和NSAID或对乙酰氨基酚来治疗疼痛。这项发明还涉及这些组合物本身，以及使用这种组合物的用途，以及包含这种组合物的药物组合物和套装。
• Novel Cyclic Amino Benzoic Acid Derivative
  申请人：Nomura Masahiro

  公开号：US20070249580A1

  公开（公告）日：2007-10-25

  The present invention relates to cyclic amino benzoic acid derivatives which are effective in therapy of lipid metabolism abnormality, diabetes and the like as a human peroxisome proliferators-activated receptor (PPAR) agonist, in particular, as an agonist against human PPARα isoform, and addition salts thereof, and pharmaceutical compositions containing these compounds. A cyclic amino benzoic acid derivative represented by the general formula (1) [wherein a ring Ar represents an aryl group which may have substituent, or the like; Y represents a C 1 -C 4 alkylene, C 2 -C 4 alkenylene, C 2 -C 4 alkynylene, or the like; Z represents an oxygen atom, sulfur atom or —(CH 2 ) n — (n represents 0, 1 or 2); X represents a hydrogen atom, halogen atom, lower alkyl group which may be substituted with a halogen atom, or the like; R represents a hydrogen atom or lower alkyl group, and —COOR substitutes for an ortho position or metha position of binding position of ring W] or a pharmaceutically acceptable salt thereof.

  本发明涉及循环氨基苯甲酸衍生物，作为人类过氧化物酶体增殖物激活受体（PPAR）激动剂，在治疗脂质代谢异常、糖尿病等方面具有有效性，特别是作为人类PPARα亚型的激动剂，以及其加成盐和含有这些化合物的药物组合物。其中，循环氨基苯甲酸衍生物的一般式（1）表示为[其中，环Ar表示可能具有取代基的芳基；Y表示C1-C4烷基、C2-C4烯基、C2-C4炔基或类似物；Z表示氧原子、硫原子或—（CH2）n—（n表示0、1或2）；X表示氢原子、卤原子、可能带有卤原子取代的低烷基或类似物；R表示氢原子或低烷基，而—COOR代替环W的结合位置的邻位或间位]或其药学上可接受的盐。
• Cyclic amino benzoic acid derivative
  申请人：Kyorin Pharmaceutical Co., Ltd.

  公开号：US07902367B2

  公开（公告）日：2011-03-08

  The present invention relates to cyclic amino benzoic acid derivatives which are effective in therapy of lipid metabolism abnormality, diabetes and the like as a human peroxisome proliferators-activated receptor (PPAR) agonist, in particular, as an agonist against human PPARα isoform, and addition salts thereof, and pharmaceutical compositions containing these compounds. A cyclic amino benzoic acid derivative represented by the general formula (1) [wherein a ring Ar represents an aryl group which may have substituent, or the like; Y represents a C1-C4 alkylene, C2-C4 alkenylene, C2-C4 alkynylene, or the like; Z represents an oxygen atom, sulfur atom or —(CH2)n— (n represents 0, 1 or 2); X represents a hydrogen atom, halogen atom, lower alkyl group which may be substituted with a halogen atom, or the like; R represents a hydrogen atom or lower alkyl group, and —COOR substitutes for an ortho position or metha position of binding position of ring W] or a pharmaceutically acceptable salt thereof.

  本发明涉及循环氨基苯甲酸衍生物，其作为人类过氧化物酶体增殖物激活受体（PPAR）激动剂在治疗脂质代谢异常、糖尿病等方面具有有效性，特别是作为人类PPARα亚型的激动剂，以及其加成盐和含有这些化合物的制药组合物。其中循环氨基苯甲酸衍生物的一般式（1）表示为[其中环Ar表示可能具有取代基的芳基基团或类似物；Y表示C1-C4烷基，C2-C4烯基，C2-C4炔基或类似物；Z表示氧原子、硫原子或—（CH2）n—（n表示0、1或2）；X表示氢原子、卤原子、可能被卤原子取代的低烷基基团或类似物；R表示氢原子或低烷基基团，而—COOR代替环W的连接位置的邻位或甲位]或其药学上可接受的盐。
• Benzoimidazole Compounds and Uses Thereof
  申请人：Cantin Louis-David

  公开号：US20120289504A1

  公开（公告）日：2012-11-15

  This invention generally relates to substituted benzoimidazole compounds, particularly methyl 2-((2-(2,6-difluoro-4-(methylcarbamoyl)phenyl)-5-methyl-1H-benzo[d]imidazol-1-yl)methyl)morpholine-4-carboxylate and salts thereof. This invention also relates to pharmaceutical compositions and kits comprising such a compound, uses of such a compound (including, for example, treatment methods and medicament preparations), processes for making such a compound, and intermediates used in such processes.

  本发明通常涉及取代苯并咪唑化合物，特别是甲基2-((2-(2,6-二氟-4-(甲基氨基)苯基)-5-甲基-1H-苯并[d]咪唑-1-基)甲基)吗啡啶-4-羧酸甲酯及其盐。本发明还涉及包含该化合物的药物组合物和试剂盒，该化合物的用途（包括治疗方法和药物制剂），制备该化合物的过程以及用于该过程的中间体。